These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22761332)

  • 1. Identification of a novel resistance mutation in parE that confers high-level resistance to moxifloxacin in Streptococcus pneumoniae.
    Zhang G; Tian W; Wang C; Feng J
    J Antimicrob Chemother; 2012 Nov; 67(11):2773-4. PubMed ID: 22761332
    [No Abstract]   [Full Text] [Related]  

  • 2. parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.
    Sun HK; Du X; DeRyke CA; Doern GV; Nicolau DP
    Int J Antimicrob Agents; 2007 Feb; 29(2):230-2. PubMed ID: 17204405
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003.
    Johnson AP; Lamagni TL; Wale M; Cavendish S; Bishop L; Alhaddad N; Warner M; Livermore DM; Duckworth G; George RC
    Int J Antimicrob Agents; 2005 Jun; 25(6):539-41. PubMed ID: 15890501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
    Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
    Hovde LB; Simonson DA; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):295-9. PubMed ID: 18053674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.
    Park HS; Jung SJ; Kwak JH; Choi DR; Choi EC
    Int J Antimicrob Agents; 2010 Jul; 36(1):97-8. PubMed ID: 20403681
    [No Abstract]   [Full Text] [Related]  

  • 9. The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
    Dobay O; Rozgonyi F; Ghidán A; Matuz M; Nagy K; Amyes SG
    J Chemother; 2006 Dec; 18(6):624-7. PubMed ID: 17267340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
    Etienne M; Croisier D; Charles PE; Lequeu C; Piroth L; Portier H; Drlica K; Chavanet P
    J Infect Dis; 2004 Oct; 190(8):1472-5. PubMed ID: 15378440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
    De Vecchi E; Nicola L; Ossola F; Drago L
    J Antimicrob Chemother; 2009 Apr; 63(4):721-7. PubMed ID: 19218275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
    Elshafie SS; Al-Kuwari J
    Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
    [No Abstract]   [Full Text] [Related]  

  • 14. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
    Alou L; Giménez MJ; Sevillano D; Aguilar L; Cafini F; Echeverría O; Pérez-Trallero E; Prieto J
    J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila.
    Almahmoud I; Kay E; Schneider D; Maurin M
    J Antimicrob Chemother; 2009 Aug; 64(2):284-93. PubMed ID: 19474069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniae.
    Dupont P; Aubry A; Cambau E; Gutmann L
    J Bacteriol; 2005 Feb; 187(4):1536-40. PubMed ID: 15687222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.
    Rupp J; Gebert A; Solbach W; Maass M
    Antimicrob Agents Chemother; 2005 Jan; 49(1):406-7. PubMed ID: 15616321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
    Cafini F; Alou L; Sevillano D; Valero E; Prieto J;
    Int J Antimicrob Agents; 2004 Oct; 24(4):334-8. PubMed ID: 15380257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E; Dalhoff A; Korfmann G
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.